PRME
Prime MedicineDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Composite grade D from latest DB weights. Momentum 95.2 / Value 40.6
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-30.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
95
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -Analysis date unavailable; returns require an exact persisted reference.
Earnings
2026-10-30
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $7.33
Why
Momentum95 · Δ7d +20.8
Value41 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-30.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Mixed signals. Wait for cleaner trend confirmation.
Catalyst clock
2026-10-30
Lead driver: Value · See fundamentals
Momentum
95
15% active weight
Current posture
7d trendFlat
Δ7d
+20.8
Δ21d
+77.3
Value
41
85% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 95.2 / Value 40.6
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$665.65M
Beta
-
Shares Out
181.38M
P/E (TTM) · Derived
-2.7
P/S (TTM)
107.82
P/FCF (TTM) · Derived
-4.07
Rev YoY
+3.5%
EPS YoY
-41.6%
Gross Margin
-81.6%
Op Margin
-4824.9%
Net Debt
-$61.25M
Current Ratio
3.05
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data